Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

被引：0
|
作者：
M. Panisset
S. Gauthier
H. Moessler
M. Windisch
机构：
[1]  McGill Centre for Studies in Ageing,
[2] Montreal,undefined
[3] Canada,undefined
[4] EBEWE Arzneimittel GmbH,undefined
[5] Unterach,undefined
[6] and,undefined
[7] JSW Research,undefined
[8] Graz,undefined
[9] Austria,undefined
来源：
Journal of Neural Transmission | 2002年 / 109卷
关键词：
Keywords: Alzheimer's disease; Cerebrolysin; neurodegeneration; neurotrophic factors; peptide derivative.;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1089 / 1104
页数：15
相关论文
共 50 条
  • [31] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [32] A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson's disease
    Chong, K. K.
    Lim, S. Y.
    Manap, M. A. A. A.
    Lim, J. L.
    Low, S. C.
    Mahadeva, S. K.
    Tan, A. H.
    MOVEMENT DISORDERS, 2018, 33 : S194 - S194
  • [33] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [34] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311
  • [35] A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Cysteamine in Huntington's Disease
    Verny, Christophe
    Bachoud-Levi, Anne-Catherine
    Durr, Alexandra
    Goizet, Cyril
    Azulay, Jean-Philippe
    Simonin, Clemence
    Tranchant, Christine
    Calvas, Fabienne
    Krystkowiak, Pierre
    Charles, Perrine
    Youssov, Katia
    Scherer, Clarisse
    Prundean, Adriana
    Olivier, Audrey
    Reynier, Pascal
    Saudou, Frederic
    Maison, Patrick
    Allain, Philippe
    von Studnitz, Erica
    Bonneau, Dominique
    MOVEMENT DISORDERS, 2017, 32 (06) : 932 - 936
  • [36] Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
    Arora, S
    Katkov, W
    Cooley, J
    Kemp, JA
    Johnston, DE
    Schapiro, RH
    Podolsky, D
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1724 - 1729
  • [37] Double-blind placebo-controlled study of velnacrine in Alzheimer's disease
    Zemlan, FP
    Keys, M
    Richter, RW
    Strub, RL
    LIFE SCIENCES, 1996, 58 (21) : 1823 - 1832
  • [38] Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial
    Heiss, Wolf-Dieter
    Brainin, Michael
    Bornstein, Natan M.
    Tuomilehto, Jaakko
    Hong, Zhen
    STROKE, 2012, 43 (03) : 630 - 636
  • [39] Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
    Guekht, Alla B.
    Moessler, Herbert
    Novak, Philipp H.
    Gusev, Evgenyi I.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2011, 20 (04): : 310 - 318
  • [40] Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study
    Jeong, Hye Won
    Yoon, Kyung Hee
    Lee, Chang Hyun
    Moon, Yoo Sun
    Kim, Do Hoon
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (02) : 311 - 319
12345